论文部分内容阅读
为降低自体骨髓移植（ＡＢＭＴ）后的复发。采用重组白细胞介素２（ｒＩＬ－２）激活骨髓（ＡＢＭ）自体移植治疗白血病１１例。１０例预处理用ＭＡＣＣ（马法兰、阿糖胞苷、环磷酰胺和环已亚硝脲）方案、１例用全身照射＋环磷酰胺方案；移植后当天开始用ｒＩＬ－２（２～４）×１０￣５Ｕ／ｄ×（１５～３０天），０～＋５天开始用Ｇ－ＣＳＦ３００μｇ／Ｌ×（５～１５天）。结果：所有患者造血都得到重建，时间缩短；移植前５例未缓解患者移植后均获完全缓解（ＣＲ），２例在移植后１０个月与１３２天复发，其它９例持续ＣＲ至１９９６年３月，ＣＲ期为５６天～３０个月。２例出现皮肤移植物抗宿主病样表现；移植中感染发生率为３６．４％。结论：ＡＢＭ自体移植治疗白血病有效，并可能诱导移植物抗白血病效应，降低ＡＢＭＴ的复发率，联合应用Ｇ－ＣＳＦ和ＩＬ－２能加速移植后造血重建。
To reduce the recurrence after autologous bone marrow transplantation (ABMT). Recombinant interleukin 2 (rIL-2) activated bone marrow (ABM) autologous transplantation for treatment of leukemia in 11 cases. 10 cases of pretreatment with MACC (Maffar, Cytarabine, Cyclophosphamide and Cyclohexamide), 1 case of systemic irradiation + Cyclophosphamide regimen; rIL-2 (2～4) started on the day after transplantation ×10 to 5 U/d× (15 to 30 days), and G-CSF 300 μg/L× (5 to 15 days) from 0 to +5 days. Results: Hematopoiesis was reconstructed and shortened in all patients; 5 patients who had not remission before transplantation received complete remission (CR) after transplantation, 2 patients relapsed after 10 and 132 days after transplantation, and the remaining 9 patients sustained CR through 1996. In March, the CR period was 56 days to 30 months. Skin graft-versus-host disease-like manifestations occurred in 2 cases; the incidence of infection during transplantation was 36.4%. Conclusion: ABM autologous transplantation is effective for treatment of leukemia, and may induce graft-anti-leukemia effect and reduce the recurrence rate of ABMT. Combined application of G-CSF and IL-2 can accelerate the hematopoietic reconstitution after transplantation.